Top-down production of drug nanocrystals: Nanosuspension stabilization, miniaturization and transformation into solid products

International Journal of Pharmaceutics

Volumn 364, Issue 1, 2008, Pages 64-75

  Van Eerdenbrugh, Bernard ^a   Van den Mooter, Guy ^a   Augustijns, Patrick ^a  

^a DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

Author keywords

Drying; Miniaturization; Nanosuspension; Solids; Stabilization

Indexed keywords

ADIPIODONE; ALBENDAZOLE; APREPITANT; AZITHROMYCIN; BUPARVAQUONE; CAMPTOTHECIN; CREMOPHOR; DANAZOL; DODECYL SULFATE SODIUM; ETOPOSIDE; FENOFIBRATE; GUM ARABIC; HYDROCORTISONE; HYDROXYPROPYLCELLULOSE; ITRACONAZOLE; MEGESTROL ACETATE; NANOCRYSTAL; NAPROXEN; OMEPRAZOLE; PACLITAXEL; PHOSPHATIDYLCHOLINE; POLOXAMER; POLYSORBATE 80; POLYVINYL ALCOHOL; POVIDONE; PREDNISOLONE; RAPAMYCIN; SPIRONOLACTONE; TRIGLIDE; TYLOXAPOL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG STABILITY; NANOSUSPENSION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SHORT SURVEY; SUSPENSION;

ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; EXCIPIENTS; HUMANS; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS; SUSPENSIONS;

EID: 53949092998     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.07.023     Document Type: Short Survey

References (116)

1. Ain-Ai A., and Gupta P.K. Effect of arginine hydrochloride and hydroxypropyl cellulose as stabilizers on the physical stability of high drug loading nanosuspensions of a poorly soluble compound. Int. J. Pharm. 351 (2008) 282-288
2. Avantium. http://www.avantium.com/index.php.
3. British Standards Institution, 2005. PAS 71:2005-Vocabulary-Nanoparticles. http://www.bsi-global.com/upload/Standards%20&%20Publications/Nanotechnologies/PAS71.pdf.
4. Chen H., Zhang Z., McNulty C., Olbert C., Yoon H.J., Lee J.W., Kim S.C., Seo M.H., Oh H.S., Lemmo A.V., Ellis S.J., and Heimlich K. A high-throughput combinatorial approach for the discovery of a cremophor EL-free paclitaxel formulation. Pharm. Res. 20 (2003) 1302-1308
5. Chiang P.C., Wahlstrom J.L., Selbo J.G., Zhou S., Wene S.P., Albin L.A., Warren C.J., Smith M.E., Roberds S.L., Ghosh S., Zhang L.L., and Pretzer D.K. 1,3-Dicyclohexyl urea nanosuspension for intravenous steady-state delivery in rats. J. Exp. Nanosci. 2 (2007) 239-250
6. Choi J.Y., Yoo J.Y., Kwak H.S., Nam B.U., and Lee J. Role of polymeric stabilizers for drug nanocrystal dispersions. Curr. Appl. Phys. 5 (2005) 472-474
7. Crisp M.T., Tucker C.J., Rogers T.L., Williams R.O., and Johnston K.P. Turbidimetric measurement and prediction of dissolution rates of poorly soluble drug nanocrystals. J. Control. Release 117 (2007) 351-359
8. Cunningham, J., Merisko-Liversidge, E., Cooper, E.R., Liversidge, G.G., 15 July 2004. Milling microgram quantities of nanoparticulate candidate compounds. World Patent WO 2004/058216 A2.
9. Dai W.G., Dong L.C., Li S., Pollock-Dove C., Chen J., Mansky P., and Eichenbaum G. Parallel screening approach to identify solubility-enhancing formulations for improved bioavailability of a poorly water-soluble compound using milligram quantities of material. Int. J. Pharm. 336 (2007) 1-11
10. Date A.A., and Patravale V.B. Current strategies for engineering drug nanoparticles. Curr. Opin. Colloid Interface Sci. 9 (2004) 222-235
11. Deng Z., Xu S., and Li S. Understanding a relaxation behavior in a nanoparticle suspension for drug delivery applications. Int. J. Pharm. 351 (2008) 236-243
12. Derjaguin B.V., and Landau L. Theory of the stability of strongly charged lyophobic sols and of the adhesion of strongly charged particles in solutions of electrolytes. Acta Phys. Chim. 14 (1941) 633-662
13. Durán J.D.G., Guindo M.C., Delgado A.V., and Gonzáles-Caballero F. Stability of monodisperse zinc sulfide colloidal dispersions. Langmuir 11 (1995) 3648-3655
14. Elan. http://www.elan.com.
15. Fasano A. Innovative strategies for the oral delivery of drugs and peptides. TIBTECH 16 (1998) 152-157
16. FDA Orange Book. http://www.fda.gov/cder/ob/default.htm.
17. Drugs@FDA. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/.
18. Feynman, R., 29 December 1959. There's plenty of room at the bottom (lecture). American Physical Society Meeting, Pasadena.
19. Gao L., Zhang D., Chen M., Zheng T., and Wang S. Preparation and characterization of an oridonin nanosuspension for solubility and dissolution velocity enhancement. Drug Dev. Ind. Pharm. 33 (2007) 1332-1339
20. Gao L., Zhang D., Chen M., Duan C., Dai W., Jia L., and Zhao W. Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions. Int. J. Pharm. 355 (2008) 321-327
21. Gardner C.R., Almarsson O., Chen H., Morissette S., Peterson M., Zhang Z., Wang S., Lemmo A., Gonzalez-Zugasti J., Monagle J., Marchionna J., Ellis S., McNulty C., Johnson A., Levinson D., and Cima M. Application of high throughput technologies to drug substance and drug product development. Comput. Chem. Eng. 28 (2004) 943-953
22. Gardner C.R., Walsh C.T., and Almarsson O. Drugs as materials: valuing physical form in drug discovery. Nat. Rev. Drug Discov. 3 (2004) 926-934
23. Gonzáles-Caballero F., and de Dios Garciá López-Durán J. Suspension formulation. In: Nielloud F., and Marti-Mestres G. (Eds). Pharmaceutical Emulsions and Suspensions, Drugs and the Pharmaceutical Sciences vol. 105 (2000), Marcel Dekker, Inc., New York 127-190
24. Grau M.J., Kayser O., and Müller R.H. Nanosuspensions of poorly soluble drugs-reproducibility of small scale production. Int. J. Pharm. 196 (2000) 155-159
25. Gupta R.B. Fundamentals of Drug Nanoparticles. In: Gupta R.B., and Kompella U.B. (Eds). Nanoparticle Technology for Drug Delivery, Drugs and the Pharmaceutical Sciences vol. 159 (2006), Taylor & Francis Group, LLC, New York 1-19
26. Hanafy A., Spahn-Langguth H., Vergnault G., Grenier P., Grozdanis M.T., Lenhardt T., and Langguth P. Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug. Adv. Drug Deliv. Rev. 59 (2007) 419-426
27. Hansell, R.J., 3 February 2005. Laboratory scale milling process. United States Patent US 2005/0023386 A.
28. Hecq J., Deleers M., Fanara D., Vranckx H., and Amighi K. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int. J. Pharm. 299 (2005) 167-177
29. Hecq J., Deleers M., Fanara D., Vranckx H., Boulanger P., Le Lamer S., and Amighi K. Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base. Eur. J. Pharm. Biopharm. 64 (2006) 360-368
30. Hecq J., Nollevaux G., Deleers M., Fanara D., Vranckx H., Peulen O., Dandrifosse G., and Amighi K. Nifedipine nanocrystals: pharmacokinetic evaluation in the rat and permeability studies in Caco-2/HT29-5M21 (co)-cultures. J. Drug Del. Sci. Technol. 16 (2006) 437-442
31. Hernández-Trejo N., Kayser O., Steckel H., and Müller R.H. Characterization of nebulized buparvaquone nanosuspensions-effect of nebulization technology. J. Drug Target. 13 (2005) 499-507
32. Horn D., and Rieger J. Organic nanoparticles in the aqueous phase-theory, experiment, and use. Angew. Chem. Int. 40 (2001) 4331-4361
33. Hu J., Johnston K.P., and Williams R.O. Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs. Drug Dev. Ind. Pharm. 30 (2004) 233-245
34. Israelachvili J. Intermolecular and Surface Forces. 2nd ed. (1992), Academic Press, London
35. Jacobs C., Kayser O., and Müller R.H. Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. Int. J. Pharm. 196 (2000) 161-164
36. Jacobs C., Kayser O., and Müller R.H. Production and characterisation of mucoadhesive nanosuspensions for the formulation of bupravaquone. Int. J. Pharm. 214 (2001) 3-7
37. Jacobs C., and Müller R.H. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm. Res. 19 (2002) 189-194
38. Jahnke S. The theory of high-pressure homogenization. In: Müller R.H., Benita S., and Böhm B.H.L. (Eds). Emulsions and Nanosuspensions for the Formulation of Poorly Soluble Drugs (1998), Medpharm Scientific, Stuttgart 177-200
39. Jia L., Wong H., Cerna C., and Weitman S.D. Effect of nanonization on absorption of 301029: ex vivo and in vivo pharmacokinetic correlations determined by liquid chromatography/mass spectrometry. Pharm. Res. 19 (2002) 1091-1096
40. Jinno J., Kamada N., Miyake M., Yamada K., Mukai T., Odomi M., Toguchi H., Liversidge G.G., Higaki K., and Kimura T. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J. Control. Release 111 (2006) 56-64
41. Joachim C. To be nano or not to be nano?. Nature Materials 4 (2005) 107-109
42. Kassem M.A., Rahman A.A.A., Ghorab M.M., Ahmed M.B., and Khalil R.M. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int. J. Pharm. 340 (2007) 126-133
43. Kayser O., Olbrich C., Yardley V., Kiderlen A.F., and Croft S.L. Formulation of amphotericin B as nanosuspension for oral administration. Int. J. Pharm. 254 (2003) 73-75
44. Keck C.M., and Müller R.H. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenization. Eur. J. Pharm. Biopharm. 62 (2006) 3-16
45. Kesisoglou F., Panmai S., and Wu Y. Application of nanoparticles in oral delivery of immediate release formulations. Curr. Nanosci. 3 (2007) 183-190
46. Kesisoglou F., Panmai S., and Wu Y. Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv. Drug Deliv. Rev. 59 (2007) 631-644
47. Kipp J.E. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int. J. Pharm. 284 (2004) 109-122
48. Kondo N., Iwao T., Masuda H., Yamanouchi K., Ishihara Y., Yamada N., Haga T., Ogawa Y., and Yokoyama K. Improved oral absorption of a poorly water-soluble drug, HO-221, by wet-bead milling producing particles in submicron region. Chem. Pharm. Bull. 41 (1993) 737-740
49. Krause K.P., and Müller R.H. Production and characterisation of highly concentrated nanosuspensions by high pressure homogenization. Int. J. Pharm. 214 (2001) 21-24
50. Kumar M.P., Rao Y.M., and Apte S. Improved bioavailability of albendazole following oral administration of nanosuspension in rats. Curr. Nanosci. 3 (2007) 191-194
51. Kumar M.P., Rao Y.M., and Apte S. Formulation of nanosuspensions of albendazole for oral administration. Curr. Nanosci. 4 (2008) 53-58
52. Langguth P., Hanafy A., Frenzel D., Grenier P., Nhamias A., Ohlig T., Vergnault G., and Spahn-Langguth H. Nanosuspension formulations for low-soluble drugs: pharmacokinetic evaluation using spironolactone as model compound. Drug Dev. Ind. Pharm. 31 (2005) 319-329
53. Lee J. Drug nano- and microparticles processed into solid dosage forms: physical properties. J. Pharm. Sci. 92 (2003) 2057-2068
54. Lee J., Lee S.J., Choi J.Y., Yoo J.Y., and Ahn C.H. Amphiphilic amino acid copolymers as stabilizers for the preparation of nanocrystal dispersion. Eur. J. Pharm. Sci. 24 (2005) 441-449
55. Lee J., and Cheng Y. Critical freezing rate in freeze drying nanocrystal dispersions. J. Control. Release 111 (2006) 185-192
56. Lee J., Choi J.Y., and Park C.H. Characteristics of polymers enabling nano-comminution of water-insoluble drugs. Int. J. Pharm. 355 (2008) 328-336
57. Lipinski C. Poor aqueous solubility-an industry wide problem in drug discovery. Am. Pharm. Rev. 5 (2002) 82-85
58. Liversidge, G.G., Phillips, C.P., Cundy, K.C., 12 April 1994. Method to reduce particle size growth during lyophilization. US Patent US 5,302,401 A.
59. Liversidge G.G., and Conzentino P. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int. J. Pharm. 125 (1995) 309-313
60. Liversidge G.G., and Cundy K.C. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs. I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int. J. Pharm. 125 (1995) 91-97
61. Liversidge, G.G., Eickhoff, W.M., Ruddy, S.B., Mueller, K.R., Roberts, M.E., Engers, D.A., 20 August 1998. Formulations of nanoparticle naproxen tablets. World Patent WO 98/35666.
62. Mansky P., Dai W.G., Li S., Pollock-Dove C., Daehne K., Dong L., and Eichenbaum G. Screening method to identify preclinical liquid and semi-solid formulations for low solubility compounds: miniaturization and automation of solvent casting and dissolution testing. J. Pharm. Sci. 96 (2007) 1548-1563
63. Marti-Mestres G., and Nielloud F. Main surfactants used in the pharmaceutical field. In: Nielloud F., and Marti-Mestres G. (Eds). Pharmaceutical Emulsions and Suspensions, Drugs and the Pharmaceutical Sciences vol. 105 (2000), Marcel Dekker, Inc., New York 1-18
64. Merisko-Liversidge E., Sarpotdar P., Bruno J., Hajj S., Wei L., Peltier N., Rake J., Shaw J.M., Pugh S., Polin L., Jones J., Corbett T., Cooper E., and Liversidge G.G. Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm. Res. 13 (1996) 272-278
65. Merisko-Liversidge, E., Linden, W., 27 March 2003. Stabilization of active agents by formulation into nanoparticulate form. World Patent WO 03/024424 A1.
66. Merisko-Liversidge E., Liversidge G.G., and Cooper E.R. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. 18 (2003) 113-120
67. Merisko-Liversidge E., McGurk S.L., and Liversidge G.G. Insulin nanoparticles: a novel formulation approach for poorly water soluble Zn-insulin. Pharm. Res. 21 (2004) 1545-1553
68. Möschwitzer J., Achleitner G., Pomper H., and Müller R.H. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur. J. Pharm. Biopharm. 58 (2004) 615-619
69. Möschwitzer J., and Müller R.H. Spray coated pellets as carrier system for mucoadhesive drug nanocrystals. Eur. J. Pharm. Biopharm. 62 (2006) 282-287
70. Mouton J.W., van Peer A., de Beule K., Van Vliet A., Donnelly J.P., and Soons P.A. Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation. Antimicrob. Agents Chemother. 50 (2006) 4096-4102
71. Müller R.H., and Böhm B.H.L. Nanosuspensions. In: Müller R.H., Benita S., and Böhm B.H.L. (Eds). Emulsions and Nanosuspensions for the Formulation of Poorly Soluble Drugs (1998), Medpharm Scientific, Stuttgart 149-174
72. Müller R.H., and Peters K. Nanosuspensions for the formulation of poorly soluble drugs. I. Preparation by a size-reduction technique. Int. J. Pharm. 2 (1998) 229-237
73. Müller R.H., Böhm B.H.L., and Grau M.J. Nanosuspensions - formulations for poorly soluble drugs with poor bioavailability - 1st communication: production and properties. Pharm. Ind. 61 (1999) 74-78
74. Müller R.H., Böhm B.H.L., and Grau M.J. Nanosuspensions - formulations for poorly soluble drugs with poor bioavailability - 2nd communication: stability, biopharmaceutical aspects, possible drug forms and registration aspects. Pharm. Ind. 61 (1999) 175-178
75. Müller R.H., Böhm B.H.L., and Grau M.J. Nanosuspensions: a formulation approach for poorly soluble and poorly bioavailable drug. In: Wise D.L. (Ed). Handbook of Pharmaceutical Controlled Release Technology (2000), Marcel Dekker, Inc., New York 345-357
76. Müller R.H., Jacobs C., and Kayser O. Nanosuspensions for the formulation of poorly soluble drugs. In: Nielloud F., and Marti-Mestres G. (Eds). Pharmaceutical Emulsions and Suspensions, Drugs and the Pharmaceutical Sciences vol. 105 (2000), Marcel Dekker, Inc., New York 383-407
77. Müller R.H., Jacobs C., and Kayser O. Nanosuspensions as particulate drug formulations in therapy-rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 47 (2001) 3-19
78. Müller R.H., and Jacobs C. Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability. Int. J. Pharm. 237 (2002) 151-161
79. Müller R.H., Kayser O., and Jacobs J. DissoCubes-a novel formulation for poorly soluble and poorly bioavailable drugs. In: Rathborn M.J., Hadgraft J., and Roberts M.S. (Eds). Modified-Release Drug Delivery Technology. Drugs and the Pharmaceutical Sciences vol. 126 (2003), Marcel Dekker, Inc., New York 135-149
80. Müller R.H., and Keck C.M. Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles. J. Biotechnol. 113 (2004) 151-170
81. Müller R.H., Möschwitzer J., and Bushrab F.N. Manufacturing of nanoparticles by milling and homogenization techniques. In: Gupta R.B., and Kompella U.B. (Eds). Nanoparticle Technology for Drug Delivery, Drugs and the Pharmaceutical Sciences vol. 159 (2006), Taylor & Francis Group, LLC, New York 21-51
82. Na G.C., Stevens H.J., Yuan B.O., and Rajagopalan N. Physical Stability of Ethyl Diatrizoate Nanocrystalline Suspension in Steam Sterilization. Pharm. Res. 16 (1999) 569-574
83. Ostrander K.D., Bosch H.W., and Bondanza D.M. An in-vitro assessment of a NanoCrystal™ beclomethasone dipropionate colloidal dispersion via ultrasonic nebulization. Eur. J. Pharm. Biopharm. 48 (1999) 207-215
84. Patravale V.B., Date A.A., and Kulkarni R.M. Nanosuspensions: a promising drug delivery strategy. J. Pharm. Pharmacol. 56 (2004) 827-840
85. Peters K., Müller R.H., and Craig D.Q.M. An investigation into the distribution of lecithins in nanosuspension systems using low frequency dielectric spectroscopy. Int. J. Pharm. 184 (1999) 53-61
86. Peters K., Leitzke S., Diederichs J.E., Borner K., Hahn H., Müller R.H., and Ehlers S. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J. Antimicrob. Chemother. 45 (2000) 77-83
87. Rabinow B.E. Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. 3 (2004) 785-796
88. Rabinow B., and Chaubal M.V. Injectable nanoparticles for efficient drug delivery. In: Gupta R.B., and Kompella U.B. (Eds). Nanoparticle Technology for Drug Delivery, Drugs and the Pharmaceutical Sciences vol. 159 (2006), Taylor & Francis Group, LLC, New York 199-229
89. Rabinow B., Kipp J., Papadopoulos P., Wong J., Glosson J., Gass J., Sun C.S., Wielgos T., White R., Cook C., Barker K., and Wood K. Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat. Int. J. Pharm. 339 (2007) 251-260
90. Rao G.C.S., Kumar M.S., Mathivanan N., and Rao M.E.B. Nanosuspensions as the most promising approach in nanoparticulate drug delivery systems. Pharmazie 59 (2004) 5-9
91. Rowe R.C., Sheskey R.J., and Weller P.J. Handbook of Pharmaceutical Excipients. 4th ed. (2003), Pharmaceutical Press, London
92. Royal Society and Royal Academy of Engineering, 2004. Nanoscience, and nanotechnology: opportunities and uncertainties. http://www.nanotec.org.uk/finalReport.htm.
93. Schöler N., Krause K., Kayser O., Müller R.H., Borner K., Hahn H., and Liesenfeld O. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis. Antimicrob. Agents Chemother. 45 (2001) 1771-1779
94. Shanbhag A., Rabel S., Nauka E., Casadevall G., Shivanand P., Eichenbaum G., and Mansky P. Method for screening of solid dispersion formulations of low-solubility compounds-miniaturization and automation of solvent casting and dissolution testing. Int. J. Pharm. 351 (2008) 209-218
95. Sigfridsson K., Forssén S., Holländer P., Skantze U., and de Verdier J. A formulation comparison, using a solution and different nanosuspensions of a poorly soluble compound. Eur. J. Pharm. Biopharm. 67 (2007) 540-547
96. SkyePharma. http://skyepharma.com.
97. Symyx. http://www.symyx.com/index.php.
98. TransForm Pharmaceuticals. http://www.transformpharma.com/.
99. Van Eerdenbrugh B., Froyen L., Martens J.A., Blaton N., Augustijns P., Brewster M., and Van den Mooter G. Characterization of physico-chemical properties and pharmaceutical performance of sucrose co-freeze-dried solid nanoparticulate powders of the anti-HIV agent loviride prepared by media milling. Int. J. Pharm. 338 (2007) 198-206
100. Van Eerdenbrugh, B., Vermant, J., Martens, J.A., Froyen, L., Van Humbeeck, J., Augustijns, P., Van den Mooter, G., submitted for publication-a. A Screening Study of Surface Stabilization in the Production of Drug Nanocrystals. J. Pharm. Sci.
101. Van Eerdenbrugh, B., Froyen, L., Van Humbeeck, J., Martens, J.A., Augustijns, P., Van den Mooter, G., submitted for publication-b. Alternative matrix formers for nanosuspension solidification: dissolution performance and X-ray microanalysis as an evaluation tool for powder dispersion. Eur. J. Pharm. Sci.
102. Van Eerdenbrugh, B., Froyen, L., Van Humbeeck, J., Martens, J.A., Augustijns, P., Van den Mooter, G., submitted for publication-c. Scaling down of drug nanosuspension production: process aspects and physico-chemical characterization. AAPS PharmSciTech.
103. Van Eerdenbrugh B., Froyen L., Van Humbeeck J., Martens J.A., Augustijns P., and Van den Mooter G. Drying of crystalline drug nanosuspensions-the importance of surface hydrophobicity on dissolution behavior upon redispersion. Eur. J. Pharm. Sci. 35 (2008) 127-135
104. Van Eerdenbrugh B., Vercruysse S., Martens J.A., Vermant J., Froyen L., Van Humbeeck G., Van den Mooter L., and Augustijns P. Microcrystalline cellulose, a useful alternative for sucrose as a matrix former during freeze-drying of drug nanosuspensions-a case study with itraconazole. Eur. J. Pharm. Biopharm. 70 (2008) 590-596
105. van Oss C.J., Giese R.F., and Costanzo P.M. DLVO and non-DLVO interactions in hectorite. Clays Clay Miner. 38 (1990) 151-159
106. van Oss C.J. Interfacial Forces in Aqueous Media (1994), Marcel Dekker, New York
107. Vergote G.J., Vervaet C., Van Driessche I., Hoste S., De Smedt S., Demeester J., Jain R.A., Ruddy S., and Remon J.P. An oral controlled release matrix pellet formulation containing nanocrystalline ketoprofen. Int. J. Pharm. 219 (2001) 81-87
108. Vergote G.J., Vervaet C., Van Driessche I., Hoste S., De Smedt S., Demeester J., Jain R.A., Ruddy S., and Remon J.P. In vivo evaluation of matrix pellets containing nanocrystalline ketoprofen. Int. J. Pharm. 240 (2002) 79-84
109. Verwey E.J.W., and Overbeek J.Th.G. Theory of the Stability of Lyophobic Colloids (1948), Elsevier, Amsterdam
110. Wahlstrom J.L., Chiang P.C., Ghosh S., Warren C.J., Wene S.P., Albin L.A., Smith M.E., and Roberds S.L. Pharmacokinetic evaluation of a 1,3-dicyclohexylurea nanosuspension formulation to support early efficacy assessment. Nanoscale Res. Lett. 2 (2007) 291-296
111. Wiedmann T.S., DeCastro L., and Wood R.W. Nebulization of NanoCrystals™: production of a respirable solid-in-liquid-in-air colloidal dispersion. Pharm. Res. 14 (1997) 112-116
112. Wong J., Brugger A., Khare A., Chaubal M., Papadopoulos P., Rabinow B., Kipp J., and Ning J. Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects. Adv. Drug Deliv. Rev. 60 (2008) 939-954
113. Wu Y., Loper A., Landis E., Hettrick L., Novak L., Lynn K., Chen C., Thompson K., Higgins R., Batra U., Shelukar S., Kwei G., and Storey D. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int. J. Pharm. 285 (2004) 135-146
114. Xiong R., Lu W., Li J., Wang P., Xu R., and Chen T. Preparation and characterization of intravenously injectable nimodipine nanosuspension. Int. J. Pharm. 350 (2008) 338-343
115. Zhang D., Tan T., Gao L., Zhao W., and Wang P. Preparation of azithromycin nanosuspensions by high pressure homogenization and its physicochemical characteristics studies. Drug Dev. Ind. Pharm. 33 (2007) 569-575
116. Zheng J.Y., and Bosch H.W. Sterile filtration of NanoCrystal™ drug formulations. Drug Dev. Ind. Pharm. 23 (1997) 1087-1093